Critical Contrast: Davide Campari-Milano (OTCMKTS:DVDCY) versus H. Lundbeck A/S (OTCMKTS:HLUYY)

Earnings and Valuation

This table compares H. Lundbeck A/S and Davide Campari-Milano”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
H. Lundbeck A/S	$2.59 billion	8.45	$209.69 million	$0.88	25.00
Davide Campari-Milano	$2.06 billion	5.50	$345.41 million	$0.26	37.88

Davide Campari-Milano has lower revenue, but higher earnings than H. Lundbeck A/S. H. Lundbeck A/S is trading at a lower price-to-earnings ratio than Davide Campari-Milano, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

H. Lundbeck A/S has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Davide Campari-Milano has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Dividends

H. Lundbeck A/S pays an annual dividend of $0.20 per share and has a dividend yield of 0.9%. Davide Campari-Milano pays an annual dividend of $0.04 per share and has a dividend yield of 0.4%. H. Lundbeck A/S pays out 22.7% of its earnings in the form of a dividend. Davide Campari-Milano pays out 15.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares H. Lundbeck A/S and Davide Campari-Milano’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
H. Lundbeck A/S	6.74%	13.74%	7.16%
Davide Campari-Milano	N/A	N/A	N/A

Summary

H. Lundbeck A/S beats Davide Campari-Milano on 7 of the 11 factors compared between the two stocks.

About H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

About Davide Campari-Milano

Davide Campari-Milano S.p.A., together with its subsidiaries, manufactures and trades in alcoholic and non-alcoholic beverages in the Americas, Europe, the Middle East, Africa, Europe, and the Asia-Pacific. Its product portfolio includes aperitifs, vodka, whisky, tequila, rum, gin, liqueurs, sparkling and still wines, and ready to drink products under approximately 50 brands. The company was founded in 1860 and is headquartered in Sesto San Giovanni, Italy. Davide Campari-Milano S.p.A. is a subsidiary of Alicros S.p.A.